Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SORAFENIB (NEXAVAR®) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.

NCT00989469 is registered in ClinicalTrials.gov with Institut du Cancer de Montpellier - Val d'Aurelle as lead sponsor.

NCT NCT00989469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00989469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SORAFENIB (NEXAVAR®) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.
Lead sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2009
Completion date
February 29, 2012
Enrollment
64 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer